Cranbury Connects^™

Support is key when dealing with rare, complex diseases, and families often require additional assistance navigating the complicated process of gaining treatment. Our Cranbury Pharmaceuticals generic team offers something new to these families in the form of FDA-approved generic products at a lower price than the brand. In addition to a lower cost alternative, Cranbury Pharmaceuticals has also added Cranbury Connects, a patient services program which provides support and financial assistance to these families. Our Care Coordinator is a single point of contact for patients and families along with prescriber offices to ensure the process of obtaining our generic products is as straightforward as possible.

In June 2024, Cranbury Pharmaceuticals debuted our FDA-approved ANDA for the first generic version of Emflaza® oral suspension (deflazacort) for the treatment of Duchenne muscular dystrophy. We're bringing a more affordable option to patients that have Duchenne Muscular Dystrophy - and there is a substantial financial burden on families that have children with this disease. With the generic deflazacort oral suspension now available to patients in the U.S., we are looking to apply this approach of extra support through care coordinators and infrastructure to other significantly complex rare diseases.

I’m proud of the entrepreneurial spirit Cranbury Pharmaceuticals embodies as well as the dedication towards creating meaningful awareness and positive impact in the rare disease space.

– Kevin Walker, Senior Vice President, Generic Division

I am professional Care Coordinator with experience in supporting treatments in the rare disease space including autoimmune diseases and oncology. My passion is helping patients access the treatments their doctors prescribe, and I am excited to be working for Cranbury Pharmaceuticals who offers lower pricing while maintaining a high degree of patient advocacy. Patients can now access better pricing without losing the support that they rely on. This is a real differentiator for Cranbury.

Navigating muscular dystrophy is very complex and without proper support can often feel overwhelming to many families. My goal is not only to educate and support the families we serve, but also being there to listen and make this journey as stress-free as possible. The work we’re doing at Cranbury Pharmaceuticals, developing complex treatments, launching Deflazacort Oral Suspension (AB Rated to Emflaza®) and providing impactful patient engagement through care management is groundbreaking work for the generics market.

– Jordan Gamble, Care Coordinator